Nvidia Expands Investment in AI Drug Discovery Leader Genesis…

Team S · 2024-12-20T14:33:33.000Z

Genesis Therapeutics, an AI-driven drug discovery company, has received additional investment from NVentures, Nvidia's venture capital arm. Founded in 2019 by Evan Feinberg and Vijay Pande, the company originated from Stanford University research and has raised over $300 million, including a $200 million Series B round in 2023. NVentures' recent undisclosed investment aims to enhance Genesis' AI platform, Genesis Exploration of Molecular Space (GEMS), which integrates generative and predictive AI to design molecules for challenging drug targets. The collaboration focuses on optimizing neural networks for 3D molecular data and leveraging Nvidia's expertise in AI hardware and software. GEMS is being used to develop oncology drugs, including inhibitors targeting PIK3CA mutations and therapies addressing resistance to checkpoint inhibitors. In immunology, Genesis is working on treatments for autoimmune disorders and genetic autoinflammatory diseases. Genesis has also partnered with major biopharma companies. Recent collaborations include a $35 million deal with Gilead Sciences, a $670 million partnership with Eli Lilly, and a multi-target effort with Genentech. Headquartered in Burlingame, California, with a lab in San Diego, Genesis employs 80 people and plans to expand further as it continues advancing its AI-driven drug discovery efforts. https://www.genengnews.com/topics/artificial-intelligence/nvidias-venture-arm-raises-stake-in-ai-drug-discoverer-genesis-therapeutics/

Member Login Get Access

Nvidia Expands Investment in AI Drug Discovery Leader Genesis… | Newnex